Trials / No Longer Available
No Longer AvailableNCT00992654
A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
A Local, Multicentre, Open Label Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The new protocol will allow the patients enrolled on A4001050 to have continuous access of Maraviroc and the treatment will not be interrupted until the drug is commercially available in India.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Open Label Treatment Access: Maraviroc | Oral dosing twice daily. The dose will depend on the optimized background therapy. |
Timeline
- First posted
- 2009-10-09
- Last updated
- 2018-09-27
Source: ClinicalTrials.gov record NCT00992654. Inclusion in this directory is not an endorsement.